文献速递膀胱癌与上尿路尿路上皮癌

ROGUE-1登记研究设计与原理:原发性T1非肌层浸润性膀胱癌多中心前瞻性登记研究

Design and Rationale of the ROGUE-1 Registry: A Multicentric Prospective Registry for Primary T1 Nonmuscle-invasive Bladder Cancer.
PubMed 文献 · Eur Urol Oncol · 2026-04-18

ROGUE-1是一项国际多中心前瞻性登记研究,计划纳入700例经二次电切确认的原发性T1膀胱癌患者,覆盖欧洲和北美18个泌尿中心。研究前瞻性采集临床、病理及流行病学数据,并进行中心病理复核,主要终点为治疗失败率(复发、高级别复发及进展为肌层浸润性疾病)。该方案性论文不报告临床结果,旨在为T1非肌层浸润性膀胱癌提供清洁的前瞻性数据集以改善风险分层。

要点

  • ROGUE-1纳入700例二次电切确认的原发性T1膀胱癌患者,覆盖18个中心。
  • 主要终点为治疗失败率,包括复发、高级别复发和进展为肌层浸润。
  • 所有标本进行中心病理复核,可选分子组分分析FFPE肿瘤转录组。

核心结论

  • ROGUE-1将提供前瞻性多中心数据集,以改善T1非肌层浸润性膀胱癌的风险分层,并识别可能从早期积极治疗或保守管理中获益的患者。

研究设计与样本

  • ROGUE-1为多中心、国际、前瞻性登记研究,计划纳入700例病理确诊的原发性T1膀胱癌患者,覆盖欧洲和北美18个泌尿中心。
  • 所有患者须经二次电切(TURB)确认T1病变,临床、病理和流行病学数据通过Castor电子数据采集平台的前瞻性电子病例报告表收集。
  • 所有标本由泌尿生殖病理专家进行中心病理复核,可选分子组分包括FFPE肿瘤标本的转录组分析,随访数据每3个月收集一次。

关键数值与推荐

  • 主要终点为治疗失败率,包括复发、高级别复发和进展为肌层浸润性疾病。
  • 随访数据收集间隔为3个月。
  • 试验注册号:ClinicalTrials.gov NCT05792033。

临床怎么用

  • 该研究为方案性论文,尚无临床结果,暂不能直接指导临床决策。
  • 研究旨在为T1非肌层浸润性膀胱癌提供清洁前瞻性数据集,未来可能辅助风险分层和治疗选择。

局限性

  • 观察性设计无法在各中心间标准化治疗。
  • 可选分子组分可能导致标本可获得性存在差异。
  • 本文为方案性论文,未报告临床结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Patients with T1 nonmuscle-invasive bladder cancer (NMIBC) face substantial risks of recurrence and progression to muscle-invasive disease. However, current risk stratification tools rely on retrospective data with significant heterogeneity in the reporting of adverse pathological features. The ROGUE-1 registry was designed to address the unmet need for a clean, prospective dataset on primary T1 bladder cancer to enable accurate risk stratification and guide clinical decision-making. METHODS: ROGUE-1 is a multicentric, international, prospective registry enrolling 700 patients with a pathologically confirmed primary diagnosis of T1 bladder cancer across 18 urology centers in Europe and North America. All patients must have T1 disease confirmed at second-look transurethral resection of bladder tumor (TURB). Clinical, pathological, and epidemiological data are prospectively collected using an electronic case report form on the Castor electronic data capture platform. Central pathology review by expert genitourinary pathologists is performed for all specimens. An optional molecular component includes transcriptome analysis of formalin-fixed paraffin-embedded tumor specimens. The primary endpoints are therapy failure rates (recurrence, high-grade recurrence, and progression to muscle-invasive disease). Follow-up data are collected at 3-mo intervals. KEY FINDINGS AND LIMITATIONS: This is a protocol paper; no clinical results are reported. A key limitation is the observational design, which precludes treatment standardization across centers. The optional molecular component may result in variable specimen availability. CONCLUSIONS AND CLINICAL IMPLICATIONS: ROGUE-1 will provide a prospective, multi-institutional dataset to improve risk stratification in T1 NMIBC and identify patients who may benefit from early aggressive treatment versus conservative management. TRIAL REGISTRATION: ClinicalTrials.gov (NCT05792033).

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. D'Andrea D, Soria F, Rouprêt M, et al. Design and Rationale of the ROGUE-1 Registry: A Multicentric Prospective Registry for Primary T1 Nonmuscle-invasive Bladder Cancer. Eur Urol Oncol. 2026. PMID: 42000298. doi:10.1016/j.euo.2026.04.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。